StockWatch
·
Biotechnology: Pharmaceutical Preparations
PatentNov 17, 2026, 04:06 PM

Akebia Therapeutics Secures Vafseo Patent Through 2043

AI Summary

Akebia Therapeutics announced a new patent granted for Vafseo (vadadustat), extending its intellectual property protection until January 18, 2043. This patent, U.S. Patent No. 12,797,375, relates to the modulation of drug-drug interactions during treatment with vadadustat. The company believes this strengthens its portfolio and enhances the long-term value of Vafseo, which is approved for treating anemia due to chronic kidney disease in adults on dialysis. Akebia currently has fourteen other vadadustat patents listed in the Orange Book with expirations between 2027 and 2036.

Key Highlights

  • New patent granted for Vafseo (vadadustat) with term extending to January 18, 2043.
  • Patent number U.S. Patent No. 12,797,375 is eligible for the Orange Book.
  • The patent covers a method of treatment related to modulating drug-drug interactions with vadadustat.
  • Akebia has fourteen other vadadustat patents listed in the Orange Book expiring between 2027 and 2036.
  • Vafseo was approved by the FDA in March 2024 for anemia due to chronic kidney disease in adults on dialysis.
  • Vafseo has been available in the U.S. since January 2025.